ALK translocation, as well as the other molecular drivers targetable by drugs in NSCLC (ROS1, MET, BRAF, RET, HER2 and NTRK), are less common [175], making it difficult to accumulate robust data on combined SRS-TKI treatment in these specific settings [171,176]. This evidence concerns the gene ALK and non-small cell lung carcinoma.